BACKGROUND: Cellular immunity is involved in spontaneous clearance of anogenital warts caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept of therapeutic vaccination. A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts. METHODS: A total of 457 subjects with anogenital warts were screened, of which 320 with HPV-6 and/or HPV-11 infection were enrolled into 2 double-blind, placebo-controlled substudies. Three doses of vaccine or placebo were administered along with either ablative therapy or podophyllotoxin. RESULTS: Although a positive trend toward clearance was seen in patients infected with only HPV-6, in neither substudy did the vaccine significantly increase the efficacy of conventional therapies, despite induction of adequate immune responses. Extensive HPV typing by polymerase chain reaction demonstrated that a majority of screened subjects (73.7%) were infected with HPV-6 and/or HPV-11 and that a large proportion (40.1%) were infected with multiple HPV types. HPV types that put subjects at high risk of development of cervical cancer were detected in 39.8% of subjects. CONCLUSIONS: Infection with multiple HPV types, including high-risk types, is common in anogenital wart disease. Therapeutic vaccination failed to increase the efficacy of conventional therapies.
RCT Entities:
BACKGROUND: Cellular immunity is involved in spontaneous clearance of anogenital warts caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept of therapeutic vaccination. A therapeutic vaccine composed of HPV-6 L2E7 fusion protein and AS02A adjuvant was evaluated in conjunction with conventional therapies in subjects with anogenital warts. METHODS: A total of 457 subjects with anogenital warts were screened, of which 320 with HPV-6 and/or HPV-11 infection were enrolled into 2 double-blind, placebo-controlled substudies. Three doses of vaccine or placebo were administered along with either ablative therapy or podophyllotoxin. RESULTS: Although a positive trend toward clearance was seen in patients infected with only HPV-6, in neither substudy did the vaccine significantly increase the efficacy of conventional therapies, despite induction of adequate immune responses. Extensive HPV typing by polymerase chain reaction demonstrated that a majority of screened subjects (73.7%) were infected with HPV-6 and/or HPV-11 and that a large proportion (40.1%) were infected with multiple HPV types. HPV types that put subjects at high risk of development of cervical cancer were detected in 39.8% of subjects. CONCLUSIONS: Infection with multiple HPV types, including high-risk types, is common in anogenital wart disease. Therapeutic vaccination failed to increase the efficacy of conventional therapies.
Authors: Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden Journal: Expert Rev Vaccines Date: 2016-03-10 Impact factor: 5.217
Authors: Hung N Luu; E Susan Amirian; Wenyaw Chan; R Palmer Beasley; Linda B Piller; Michael E Scheurer Journal: J Infect Dis Date: 2012-01-13 Impact factor: 5.226
Authors: Alan G Nyitray; Mihyun Chang; Luisa L Villa; Roberto J Carvalho da Silva; Maria Luiza Baggio; Martha Abrahamsen; Mary Papenfuss; Manuel Quiterio; Jorge Salmerón; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: J Infect Dis Date: 2015-02-03 Impact factor: 5.226
Authors: Zhenhua Lin; Anna V Yemelyanova; Ratish Gambhira; Subhashini Jagu; Craig Meyers; Reinhard Kirnbauer; Brigitte M Ronnett; Patti E Gravitt; Richard B S Roden Journal: Am J Pathol Date: 2008-12-18 Impact factor: 4.307
Authors: Balasubramanyam Karanam; Ratish Gambhira; Shiwen Peng; Subhashini Jagu; Dae-Jin Kim; Gary W Ketner; Peter L Stern; Robert J Adams; Richard B S Roden Journal: Vaccine Date: 2008-12-16 Impact factor: 3.641